Mirogabalin

Summary

Mirogabalin (CHEMBL3545125) is a phase-3 clinical-stage small molecule (ATC N02BF03) targeting SLC15A1 and SLC15A2; indicated across 4 conditions including fibromyalgia and neuralgia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N02BF03
• Targets: 2 (SLC15A1, SLC15A2)
• Indications: 4 conditions
• Clinical trials: 6
• Chemistry: 209.28 Da · C12H19NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545125
Name	Mirogabalin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	59509752
ATC	N02BF03
Molecular formula	C12H19NO2
Molecular weight	209.28
InChIKey	FTBQORVNHOIASH-CKYFFXLPSA-N

SMILES: CCC1=C[C@@H]2[C@H](C1)C[C@@]2(CC(=O)O)CN

IUPAC name: 2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid

Also known as: Mirogabalin, Mirogabalina, Mirogabaline, MIROGABALIN

Parent form; salt/anhydrous children: CHEMBL3545257

Patent coverage: 91 distinct patent families (172 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC15A1	Peptide transporter 1			0%	P46059
SLC15A2	Peptide transporter 2			0%	Q16348

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): SLC15A1, SLC15A2.

Top Reactome pathways

4 total, by targets touching each:

Pathway	Targets	Genes
Transport of small molecules	1	SLC15A1
R-HSA-425393	1	SLC15A1
SLC-mediated transmembrane transport	1	SLC15A1
Proton/oligopeptide cotransporters	1	SLC15A1

Dominant GO biological processes

GO term	Targets
protein transport	2
dipeptide import across plasma membrane	2
tripeptide import across plasma membrane	2
oligopeptide transport	2
peptide transport	2
transmembrane transport	2
proton transmembrane transport	2
monoatomic ion transport	1
peptidoglycan transport	1
xenobiotic transport	1
dipeptide transport	1
renal absorption	1
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway	1
antibacterial innate immune response	1
transport across blood-brain barrier	1

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
fibromyalgia	3	MONDO:0005546	EFO:0005687
neuralgia	3	MONDO:0021667	EFO:0005762
diabetic neuropathy	2	MONDO:0006626	EFO:1000783

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	3
PHASE3	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07451431	PHASE4	RECRUITING	Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain
NCT03901352	PHASE3	COMPLETED	Study of Mirogabalin for Central Neuropathic Pain
NCT04094662	PHASE3	COMPLETED	A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain
NCT06328062	Not specified	RECRUITING	Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA
NCT06711978	Not specified	NOT_YET_RECRUITING	Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors
NCT07157852	Not specified	RECRUITING	The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

42 molecules share ≥1 primary target. Top 42 by shared-target count:

Molecule	Source	Status	Shared targets
Ampicillin	ChEMBL + PubChem	Phase 4 (approved)	SLC15A1, SLC15A2
cefaclor	ChEMBL + PubChem	Phase 4 (approved)	SLC15A1, SLC15A2
Cefadroxil	ChEMBL + PubChem	Phase 4 (approved)	SLC15A1, SLC15A2
Ceftibuten	ChEMBL + PubChem	Phase 4 (approved)	SLC15A1, SLC15A2
cephalexin	ChEMBL + PubChem	Phase 4 (approved)	SLC15A1, SLC15A2
aminolevulinic acid	PubChem	Approved	SLC15A1, SLC15A2
Amoxicillin	PubChem	Approved	SLC15A1, SLC15A2
Captopril	PubChem	Approved	SLC15A1, SLC15A2
Cefdinir	PubChem	Approved	SLC15A1, SLC15A2
Cefepime	PubChem	Approved	SLC15A1, SLC15A2
Cefixime	PubChem	Approved	SLC15A1, SLC15A2
Cefotaxime	PubChem	Approved	SLC15A1, SLC15A2
Cefpodoxime	PubChem	Approved	SLC15A1, SLC15A2
Cefuroxime	PubChem	Approved	SLC15A1, SLC15A2
Cephapirin	PubChem	Approved	SLC15A1, SLC15A2
Cloxacillin	PubChem	Approved	SLC15A1, SLC15A2
Dicloxacillin	PubChem	Approved	SLC15A1, SLC15A2
Enalapril	PubChem	Approved	SLC15A1, SLC15A2
Oseltamivir	PubChem	Approved	SLC15A1, SLC15A2
oseltamivir acid	PubChem	Approved	SLC15A1, SLC15A2
Oxacillin	PubChem	Approved	SLC15A1, SLC15A2
Penicillin G	PubChem	Approved	SLC15A1, SLC15A2
Valacyclovir	PubChem	Approved	SLC15A1, SLC15A2
CEPHRADINE	ChEMBL	Phase 4 (approved)	SLC15A1
CYCLACILLIN	ChEMBL	Phase 4 (approved)	SLC15A2
CARNOSINE	ChEMBL	Phase 3	SLC15A2
LEVULINIC ACID	ChEMBL	Phase 3	SLC15A2
Cefazolin	PubChem	Approved	SLC15A1
Cefoxitin	PubChem	Approved	SLC15A1
Ceftazidime	PubChem	Approved	SLC15A1
Ceftriaxone	PubChem	Approved	SLC15A1
enalaprilat dihydrate	PubChem	Approved	SLC15A1
Floxuridine	PubChem	Approved	SLC15A1
Fosinopril	PubChem	Approved	SLC15A2
Glycine	PubChem	Approved	SLC15A1
Levodopa	PubChem	Approved	SLC15A1
lisinopril	PubChem	Approved	SLC15A1
Methyldopa	PubChem	Approved	SLC15A1
Penicillin V	PubChem	Approved	SLC15A1
prezatide	PubChem	Approved	SLC15A2
valine	PubChem	Approved	SLC15A1
zinc sulfate, unspecified form	PubChem	Approved	SLC15A1